The company said in a statement, that one of its subsidiaries got the final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic version of Glumetza, Metformin Hydrochloride extended release tablets 500 mg and 1,000 mg.
"These Metformin Hydrochloride extended release tablets are therapeutic equivalents of Santarus Inc's Glumetza tablets," the statement said.
The tablets may have an annual sales of around $1.2 billion in the US, the company added.
This website uses cookies.